• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Keywords » esketamine

Items Tagged with 'esketamine'

ARTICLES

Clinical Update

How Long Should We Continue Esketamine?

February 1, 2025
Steven Hamilton, PhD, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Steven Hamilton, MD, PhD. The Permanente Medical Group, Department of Psychiatry, Kaiser Permanente San Francisco Medical Center.

Dr. Hamilton has no financial relationships with companies related to this material.

Response to esketamine (Spravato) is brisk and bold, but how do you keep patients well over the long term? We look at new research on continuation, tapering, and switching strategies.


Read More
Research Update

Esketamine vs Quetiapine in ­Treatment-Resistant Depression

November 1, 2024
Ivy Song, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Ivy Song, MD. Dr. Song has no financial relationships with companies related to this material.

Esketamine outperforms quetiapine in TRD remission rates, but the clinical significance of this difference remains uncertain.


Read More
shutterstock_2530609551.jpg

Top 10 Findings: Lithium, Lumateperone, and Lavender

October 21, 2024
Chris Aiken, MD and Kellie Newsome, PMHNP

New studies change how we think about lithium and weight gain, and updates on lumateperone, lavender, and esketamine in depression. 




Read More
shutterstock_2485974649.jpg

Ketamine Assisted Therapy Part III

July 8, 2024
Chris Aiken, MD, Kellie Newsome, PMHNP, and Kyle T. Greenway, MD, MSc

Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it.




Read More
shutterstock_2475242883.jpg

Ketamine Assisted Therapy Part II

July 1, 2024
Kellie Newsome, PMHNP, Chris Aiken, MD, and Kyle T. Greenway, MD, MSc

Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it.




Read More
shutterstock_2479647635.jpg

Ketamine Assisted Therapy Part I

June 24, 2024
Chris Aiken, MD, Kellie Newsome, PMHNP, and Kyle T. Greenway, MD, MSc

Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it. 




Read More
Expert Q&A

Ketamine Use and Misuse

April 1, 2024
Keith A. Trujillo, PhD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

CATR_QA2_KeithTrujillo_headshot.jpegKeith A. Trujillo, PhD.  

Emeritus Professor of Psychology, California State University, San Marcos, CA.

Dr. Trujillo has no financial relationships with companies related to this material.

Ketamine and esketamine represent some of the most powerful rapid-acting agents in our armamentarium of treatments for depression. However, ketamine is also an addictive substance, and there is emerging evidence that the widespread use of ketamine may be causing more patient harms than we were previously aware of. Here, Dr. Trujillo discusses how to use ketamine safely in clinical practice.


Read More
Clinical Update

Six Recent Disappointments in Psychiatric Research

February 1, 2024
Chris Aiken, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Find out where standard therapies like cariprazine and esketamine have failed in recent trials, along with novel medications like minocycline, zuranolone, pimavanserin, and NAC.


Read More
ketamine canstockphoto17640753.png
CARLAT WEBINAR

Ketamine and the Evolving Psychopharmacologic Pipeline for Depression

December 8, 2023
Robert C. Meisner, MD

0.50 CME Credits. Robert Meisner, MD, explores the latest developments in psychiatric treatment with ketamine and esketamine, including their differences and emerging insights for clinicians.


Read More
Screen Shot 2023-11-12 at 1.13.49 PM.png

Ketamine: Six New Findings Part 2

November 13, 2023
Chris Aiken, MD and Kellie Newsome, PMHNP

New research brings clarity to the big ketamine questions. How does it compare to ECT and antipsychotics? How much of it is placebo? Which is more effective – ketamine or esketamine? How do you sustain the benefits? Does it work better with psychotherapy?




Read More
More Articles Tagged with 'esketamine'
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.